The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Estimation of maximum tolerated dose and minimum efficient dose of BP-C1 in the treatment of stage IV breast cancer patients: A phase I response surface pathway designed study.
Stig Einride Larsen
No relevant relationships to disclose
Sagita Dewi
No relevant relationships to disclose
Vichien Srimuninnimit
No relevant relationships to disclose
Yen-Shen Lu
No relevant relationships to disclose
Tjakra Manuaba
No relevant relationships to disclose
Steen Lindkaer Jensen
No relevant relationships to disclose